ArticleThe oncologist2025
Clinical features and prognostic factors of intravascular large B-cell lymphoma: a cohort study of 20 patients from 2018 to 2024.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Histologic Diagnosis of Intravascular Large B-Cell Lymphoma After Endovascular Thrombectomy: A Case Report of a Rare and Incidental Finding.Reports (MDPI) · 2026Article
- Intravascular large B-cell lymphoma mimicking an orbital mass lesion and bilateral cavernous sinus syndrome: A case report.Oncology letters · 2026Article
- Beyond infection-a ferritin-LDH-IL-10 triad to unmask intravascular lymphoma in fever of unknown origin: a case report and literature review.Frontiers in medicine · 2026Article
- Article
- Pulmonary intravascular large B-cell lymphoma misdiagnosed as allergic pneumonia: a case report and literature review.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIntravascular large B-cell lymphoma (IVLBCL) is a rare, aggressive lymphoma characterized by lymphoma cells proliferating within small blood vessels, lacking an extravascular mass. Its low incidence complicates diagnosis and treatment.
methodsThis study analyzed 20 IVLBCL patients diagnosed between 2018 and 2024, aiming to describe their clinical presentations, diagnostic procedures, treatment, and outcomes.
resultsAll patients had stage IV disease with poor ECOG performance status and high-risk IPI scores (100% ≥ 4). Common symptoms included fever (65%), impaired consciousness (30%), and respiratory issues (25%). Laboratory findings revealed cytopenias (60% anemia, 60% thrombocytopenia, and 35% leukocytopenia), elevated lactate dehydrogenase (20/20, 100%), C-reactive protein (14/14, 100%), and erythrocyte sedimentation rate (11/12, 91.7%). Five of six patients had extreme IL-10 elevation. Imaging studies showed a high incidence of adrenal gland involvement (9/20, 45%), reproductive system involvement (7/20, 35%), central nervous system (CNS) involvement (6/20, 30%), and splenomegaly (9/20, 45%). Nineteen of 20 patients were non-GCB (CD10-MUM1+). Seven of 14 patients tested positive for CD5. Eighteen of 20 patients received CD20 antibody plus chemotherapy as first-line therapy, with complete responses (CRs) achieved in 7 of 18 patients. After a median follow-up of 42.4 months, the 1-year and 2-year overall survival rates were 71.3% and 65.4%, respectively. Unfavorable risk factors included central nervous system (CNS) and bone marrow (BM) involvement, and elevated creatinine.
conclusionThe study highlights the high incidence of adrenal and reproductive system involvement in IVLBCL, with CNS, BM, and elevated creatinine contributing to rapid disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.